Publications by authors named "Maria L Veronese"

Claim this Profile
P
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results.
Iben Spanggaard, Marc Matrana, Caio Rocha Lima, Amit Mahipal, Maria Vieito, Maria Luisa Veronese

Oncologist· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Maria Luisa Veronese

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Maria Luisa Veronese

Nat Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view.
Christophe Le Tourneau, Fabrice André, Åslaug Helland, Linda Mileshkin, Warnyta Minnaard, Maria Luisa Veronese

Eur J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Maria Luisa Veronese

N Engl J Med· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
George D Demetri, Paolo G Casali, Jean-Yves Blay, Margaret von Mehren, Jeffrey A Morgan, Maria Luisa Veronese

Clin Cancer Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of hypertension associated with BAY 43-9006.
Maria Luisa Veronese, Ari Mosenkis, Keith T Flaherty, Maryann Gallagher, James P Stevenson

J Clin Oncol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
Maria Luisa Veronese, Kenneth Algazy, Lisa Bearn, Beth Eaby, Jane Alavi

Cancer Invest· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors.
Maria Luisa Veronese, Keith Flaherty, Amy Kramer, Barbara A Konkle, Mark Morgan

Cancer Chemother Pharmacol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal antibodies in the treatment of colorectal cancer.
Maria Luisa Veronese, Peter J O'Dwyer

Eur J Cancer· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of mibefradil on CYP3A4 in vivo.
Maria L Veronese, Lisa P Gillen, Ellen P Dorval, Walter W Hauck, Scott A Waldman

J Clin Pharmacol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Maria L Veronese, Lisa P Gillen, Joanne P Burke, Ellen P Dorval, Walter W Hauck

J Clin Pharmacol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis